Pharmaceutical equipment companies have hit the IPO, the industry can be expected in spring?

【Pharmaceutical Network Market Analysis】For pharmaceutical equipment enterprises, with the help of capital, they can achieve large-scale expansion, help product transformation and upgrading, and then help revenue growth
.
Recently, a number of pharmaceutical equipment companies have rushed to IPO.

Pharmaceutical equipment industry (Image source: Pharma Network) Pharmaceutical equipment companies have knocked on the door of capital On October 27, the IPO of Zhejiang Yaguang Technology Co.
, Ltd.
(hereinafter referred to as "Matt Technology") was approved, and the sponsor of the company's issuance was Guojin Securities
.
Matt Technology is an enterprise mainly engaged in the research and development, design, production and sales of pharmaceutical equipment, the company intends to be listed on the main board of the Shanghai Stock Exchange, this public offering of 33.
50 million new shares, accounting for 25.
0336%
of the total share capital after the issuance.
The issuance of shares is all new shares and does not involve the public offering of shares
by the company's shareholders.
This time, Matt Technology intends to raise 517 million yuan, which will be used for an annual output of 800 sets (sets) of chemical and pharmaceutical equipment projects, an annual output of 50 sets of MVR and related energy-saving and environmental protection products construction projects, supplementary working capital and repayment of bank loans
.
Also in October, Liaoning Chunguang Pharmaceutical Equipment Co.
, Ltd.
(hereinafter referred to as Chunguang Pharmaceutical Equipment) updated the review of listing applications, and the results of the 55th review meeting of the Listing Committee of the Beijing Stock Exchange in 2022 have been released, and the company meets the issuance conditions, listing conditions and information disclosure requirements
.
The main business of Chunguang Pharmaceutical is the research and development, production and sales
of pharmaceutical and food packaging equipment.
The sponsor of the company's offering is China Securities Construction Investment Co.
, Ltd.
, and Chunguang Pharmaceutical intends to issue no more than 25.
000 million shares (without considering the over-allotment option).

The company intends to raise 250 million yuan for the construction project of intelligent automation equipment production base and supplementary working capital project
.
From the information disclosed by the two companies, it can be seen that the company's fundraising is mainly used to improve the company's production capacity and intelligent manufacturing capabilities, which shows that production capacity and intelligent manufacturing capabilities may be important competitiveness
of pharmaceutical machinery enterprises in the future.
Can the industry be expected in spring? Pharmaceutical equipment is located in the upstream position of the pharmaceutical industry and is one of the important components of
the pharmaceutical industry.
Behind the impact of pharmaceutical machinery companies on IPOs, the pharmaceutical equipment industry is ushering in development opportunities
.
On the one hand, with the aging and the increase in consumption level, the strong demand for drugs has promoted the development of the pharmaceutical equipment industry, and at the same time, emerging treatment methods including targeted drugs, biomacromolecules and CGT have emerged in recent years, bringing new increments
to the pharmaceutical industry.
On the other hand, domestic substitution is timely
.
Since 2020, under the background of delayed delivery of imported pharmaceutical equipment, domestic pharmaceutical equipment with strength has entered the stage and won the attention and recognition
of pharmaceutical companies.
In the post-epidemic era, with the improvement of the R&D and innovation capabilities of domestic pharmaceutical machine enterprises, it is expected to continue to make breakthroughs in the middle and high-end fields, and domestic substitution can be expected
in the future.
In the face of considerable market space, pharmaceutical machinery companies need to actively deploy in order to seize opportunities, and this is inseparable from capital investment
.
At present, many leading enterprises are also actively expanding production
by raising funds.
For example, Dongfulong recently announced that the company's proposed capital increase of no more than 3.
2 billion yuan was approved, mainly to increase the production capacity of pharmaceutical equipment and replenish working capital
.
According to the industry, capital is the lifeblood of the survival and development of enterprises, so pharmaceutical machinery companies plan ahead to lay out financing channels, which is conducive to expanding the scale of enterprises, helping product transformation and breakthrough, and helping enterprises resist risks
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.